Dr Adam P Lightfoot

My profile

Biography

Adam Lightfoot is Senior Lecturer in Physiology in the Department of Life Science at Manchester Metropolitan University. He was awarded a BSc (Hons) in Biomedical Sciences in 2006,  and MRes in Jan Lotvall’s lab at Gothenberg University, in Cell Biology in 2007. Adam was awarded his PhD in 2011, examining the role of skeletal muscle as an endocrine organ, working with Anne McArdle and Richard Griffiths at the University of Liverpool.

Postdoctoral work followed with a Mersey Kidney First award, investigating mitochondrial dysfunction and skeletal muscle weakness in patients with chronic kidney disease (CKD). Adam was appointed Research Fellow in 2013, working alongside Bob Cooper, examining the cellular and molecular mechanisms of muscle weakness in patients with myositis, funded by Myositis UK.

Adam joined Manchester Met in 2016 as Lecturer, and continued research in myositis, with awards from The Royal Society & The Physiological Society, appointed Senior Lecturer in 2018. Adam took sabbatical in 2021, taking a role in Obesity at Novo Nordisk. Adam re-joined Manchester Met in January 2024 as Senior Lecturer in Physiology, leading an on-going research portfolio, in rare metabolic, mitochondrial diseases, obesity and ageing.

Adam has received in the region of ~£800k in competitive grant funding to-date, with awards from Myositis UK, The Myositis Association, The Royal Society & The Physiological Society. He has an array of high-quality publications in leading journals with the field: FASEB J, Annals of the Rheumatic Dieases, Arthritis & Rheumatology, Journal of Physiology.

Interests and expertise

I am a cell and molecular physiologist, with a specific interest in mechanistic research in neuromuscular, mitochondrial, metabolic diseases and obesity. My research falls within the following themes:

Idiopathic Inflammatory Myopathies (myositis): My research since 2013 has been investigating the non-immune cell mediated mechanisms of muscle weakness in patients with myositis. My lab has developed human pre-clinical models of myositis  and used primary patient biopsy samples to study mitochondrial dysfunction, UPR and redox dis-homeostasis, in an effort to provide insight into new avenues for therapy.

Muscle-adipose crosstalk: We are interested in the bi-directional communication and signalling which occurs between skeletal muscle and adipose tissue in the context of sarcopenic obesity (SO). Sarcopenic obesity sits at the axis of the ageing and obesity epidemic and remains a poorly characterised and understood.  The loss of muscle mass and function accompanying increased adiposity (myosteatosis) is an unmet clinical need, moreover there is a paucity of evidence in understanding the mechanisms responsible for this phenotype. My lab is focused modelling that crosstalk, using state-of-the-art human co-culture systems and metabolic analyses to disentangle factors and mechanisms.

Development of human relevant pre-clinical models of  skeletal muscle: In collaboration with Dr Nasser Al-Shanti, we are driven to develop better human pre-clinical platforms of muscle disease, as a platform for mechanistic discovery. We have developed co-culture techniques and methods, as well as overexpressor cell lines, to model human disease in vitro.

I am accepting applications for self-funded MRes and PhD students  - please email me directly to discuss.

Research outputs

I am an experienced researcher and academic, with expertise in the study of mitochondrial dysfunction and redox biology in neuromuscular diseases, ageing, rare metabolic diseases and obesity.